Dr. Anand has led more than 60 investments with 20 successful exits including 2 Unicorn exits in Biotech & Pharma. Some of the notable exits have been as follows: BioVex-Acquired by Amgen for USD1 Billion, Matrix Labs-Acquired by Mylan Labs for USD 1.1Billion, Idun labs-Acquired by Pfizer, eBeecare by Raffles Hospital & Acquisition of Epsilon-Oncology Formulations company by Amneal Pharma (USA).
Prior to GOVIN, Anand served as the Senior Vice President & Head of the Investment & Spin-Off Management Division at A*ccelerate, Innovation & Commercialisation arm of A*STAR, Singapore (2009-2012). Prior to A*ccelerate, Anand served as a member of the Direct Investments Life Sciences team at Temasek Holdings, Singapore (2001-2009)
21 Bukit Batok Crescent
#05-74 WCEGA Tower
© 2021 SAI All rights reserved